Advertisement
UK markets close in 2 hours 2 minutes

  • FTSE 100

    8,049.68
    +9.30 (+0.12%)
     

  • FTSE 250

    19,617.57
    -101.80 (-0.52%)
     

  • AIM

    753.59
    -1.10 (-0.15%)
     

  • GBP/EUR

    1.1661
    +0.0017 (+0.14%)
     

  • GBP/USD

    1.2463
    +0.0000 (+0.00%)
     

  • Bitcoin GBP

    50,682.78
    -2,317.66 (-4.37%)
     

  • CMC Crypto 200

    1,345.23
    -37.35 (-2.71%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.37
    -0.44 (-0.53%)
     

  • GOLD FUTURES

    2,327.70
    -10.70 (-0.46%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,855.01
    -233.69 (-1.29%)
     

  • CAC 40

    7,971.37
    -120.49 (-1.49%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

AstraZeneca bets another $140 mln on Moderna's "messenger" drugs

Reuters - UK Focus

LONDON, Aug 10 (Reuters) - AstraZeneca (NYSE: AZN - news) has invested another $140 million in Moderna Therapeutics, the U.S (Other OTC: UBGXF - news) . biotech "unicorn" which already has a cash pile of around $1 billion and is developing drugs based on a molecule known as messenger RNA.

The British drugmaker said on Wednesday that the new investment, part of a preferred-stock financing, lifted its stake in Moderna to 9 percent. AstraZeneca first invested in Moderna in 2013.

Messenger RNA (mRNA) carries the recipe for making proteins inside the body. Using it as a medicine could offer a new way to tackle many hard-to-treat diseases, from cancer to infections to heart and kidney disorders.

In effect mRNA serves as software that can be injected into the body to instruct ribosomes, the "3D-printers" found inside cells, to churn out the desired proteins.

ADVERTISEMENT

Moderna's work is still at an early stage. It (Other OTC: ITGL - news) has two Phase I studies underway for mRNA-based infectious disease vaccines, and last month Moderna and AstraZeneca filed for approval to run another Phase I study of a vascular disease treatment.

Moderna also has strategic agreements with Alexion Pharmaceuticals, Merck (LSE: 0O14.L - news) and Vertex Pharmaceuticals. (Reporting by Ben Hirschler; Editing by Greg Mahlich)